Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street
This article was originally published in RPM Report
There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?
You may also be interested in...
As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling
Troubled by slower Byetta growth and uncertainty around the development of a long-acting version, Amylin will cut 25 percent of its San Diego workforce.
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.